Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of "Moderate Buy" by Brokerages

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fourteen analysts that are covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $75.00.

A number of analysts recently weighed in on KROS shares. Jefferies Financial Group assumed coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They issued a "buy" rating for the company. Wells Fargo & Company boosted their target price on Keros Therapeutics from $88.00 to $111.00 and gave the company an "overweight" rating in a research note on Wednesday, December 11th. TD Cowen cut Keros Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Guggenheim cut Keros Therapeutics from a "buy" rating to a "neutral" rating in a research note on Monday, December 16th. Finally, Scotiabank reduced their price target on Keros Therapeutics from $77.00 to $44.00 and set a "sector outperform" rating on the stock in a research note on Friday, December 13th.

Keros Therapeutics Stock Down 2.2 %

NASDAQ:KROS traded down $0.33 during trading hours on Friday, hitting $14.56. 1,609,744 shares of the company traded hands, compared to its average volume of 905,352. The company has a market cap of $589.78 million, a PE ratio of -2.79 and a beta of 1.43. Keros Therapeutics has a one year low of $13.96 and a one year high of $73.00. The firm's 50-day simple moving average is $41.71 and its 200-day simple moving average is $48.34.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business's revenue was up 4750.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.33) earnings per share. As a group, equities research analysts expect that Keros Therapeutics will post -5.26 EPS for the current year.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. KBC Group NV increased its stake in Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company's stock worth $73,000 after buying an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after buying an additional 280 shares during the period. Values First Advisors Inc. purchased a new position in Keros Therapeutics in the third quarter valued at $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Keros Therapeutics in the second quarter valued at $128,000. Finally, LMR Partners LLP purchased a new position in Keros Therapeutics in the third quarter valued at $213,000. Institutional investors and hedge funds own 71.56% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.